Prescription drugs
Prescription drugs
We help navigate pharmacy benefit challenges
Milliman prescription drugs solutions
PBM contracting and management
Pharmacy plan design
Medicare Part D
Milliman prescription drugs insight
Demonstrations and consolidations: A first view of the 2025 PDP market
This article highlights the key changes to premiums and plan offerings in the prescription drug plan (PDP) market.
Patterns in psychotropic and other select nervous system prescription utilization
Emerging trends in pharmacy shopping and related overdoses
Manage pharmacy spending with precision medicine via uplift modeling
This white paper focuses on one approach for improving drug utilization management: precision medicine through a method known as uplift modeling.
The evolution of biosimilars in the United States
Biosimilars recently have made significant strides toward greater acceptance and utilization since their first U.S. approval in 2015, although challenges persist.
Commercial drug trends: 2024 release
This report provides insights into pharmacy cost and utilization trends based on our analysis of the Milliman Consolidated Health Cost Guidelines Sources Database.
The shifting Medicare landscape: Results from 2024 open enrollment
2024 brings significant changes to the Part D program, resulting in larger than average shifts in member enrollment
CMS Cell and Gene Therapy Access Model
Exploring the benefits, limitations, and considerations for expansion.
A prescription for change: How the 2025 Medicare Part D risk adjustment (RxHCC) model overhaul will affect risk scores
Following significant changes to the 2024 Part C risk adjustment model, Medicare Advantage organizations (MAOs) will experience another material model change in 2025—this time for Part D.
Impact of the Inflation Reduction Act on plans seeking creditable coverage
Plan sponsors seeking creditable coverage for their retiree prescription drug plans may need to enrich coverage in 2025, due to effects from the Inflation Reduction Act (IRA).
Battle royale: Part D EGWPs vs. RDS plans in the era of the Inflation Reduction Act
In this article, we discuss the potential impacts of the IRA on EGWPs, and highlight key factors plan sponsors should consider when evaluating options for retiree benefits in 2025 and beyond.
Milliman prescription drug products
Milliman Payer Network Check
MyRxConsultant
IntelliScript
Medicare Suggest
Milliman Specialty Pharmacy Insights
Milliman Price Transparency Solutions for Payers and Providers
